Debra Schwab Brandt, D.O.
Northwestern Connecticut Oncology/Hematology Associates, LLP
200 Kennedy Drive New Milford Cancer Center
Sharon, CT 06069 Torrington, CT 06790 21 Elm St, New Milford, CT 06776 ______________________________________________________________________ Specialties - Medical Hematology and Medical Oncology and Internal Medicine 1998 - present
Private Practice- Northwest Connecticut Oncology/Hematology Associates
Director of Clinical Trials - Responsible for Overseeing Clinical
Trials Hospital Privledges - Charlotte Hungerford Hospital, New Milford Hospital,
Postdoctoral Training Fellowship: Yale University- New Haven, Connecticut 7/95 - 6/98 Hematology/Oncology Department Residency: UMDNU-Robert Wood Johnson University Hospital-New Brunswick, N.J/ 7/93 - 6/95 Internal Medicine Department Residency: Beth Israel Medical Center-New York, N.Y. 7/92 - 6/93 Internal Medicine Department
Internship: Union Hospital-Rotating Internship-Union, N.J. 7/91-6/91
Education Medical:
Board Certification: Osteopathic National Boards 1991 Internal Medicine 1995 Medical
Debra Schwab Brandt, D.O.
Northwestern Connecticut Oncology/Hematology Associates, LLP
______________________________________________________________________
Honors and Awards Sigma Sigma Phi - National Honor and Service Society. Ram’s Head Award - Expertise in Osteopathic manipulation Connecticut Magazine: Best Doctor in Connecticut Award as Chosen by Peers 2004
Research
1) Research Director at NW Oncology/Hematology Associates. Participate in ECOG,
Yale Oncology Network, and pharmaceutical company driven protocols.
2) Laboratory Experience: One year exploring the biochemical mechanism for
synergistic activity between fludarabine and cyclophosphamide (with Dr. Ed Chu- Yale University).
3) Clinical Protocol Investigator: Phase II trial of cytoxan, vincristine, and fludarabine in
patients with CLL and primary and refractory low grade non-hodgkin’s lymphoma.
Publications 1) Salloum, E., Brandt, D., CarideE., et al.: Gallium Scans in the Management of
Patients with Hodgkin’s Disease: A Study of 101 Patients: JCO 15, 518-527, 1997.
2) Brandt, D. and Chu, E.: Future Challenges in the Clinical Development of
Thymidylate Synthase Inhibitor Compounds, Onc. Res. 9: 403-410, 1998.
3) Brandt, D. and Chu, E.: The development of the TS Inhibitor Compounds in the
treatment of human colorectal cancer., Advances in Colon Cancer, 10, 1997.
4) Brandt, D. and Chu, E.: Rescue agents for 5-fluorouracil., Advances in Colon
5) Fischer, D.S., Knobf, T.M. and Durivage, H.J.: The Cancer Chemotherapy
Handbook,. Mosby Yearbook Inc. 1997. Aided in the research and writing of the chapter on combination chemotherapy.
Appointments 2002-present: Transfusion Committee-chair 1999-present: Institutional Review Board 1999-present: Pharmacy and Therapeutics Committee 1998-present: Cancer Committee 2000-present: Programming Committee Memberships ASCO, AMA, AOA, ASH, Connecticut Oncology Associates, ECOG, Yale Oncology Network
Preferences in Game Logics Abstract even excluding the possibility that an agent might value op-tions equally. Models of social procedures that do not re- We introduce a Game Logic with Preferences ( GLP ), quire one to completely specify the preferences of agents which makes it possible to reason about how information are thus highly desirable. Gal and Pfeffer [9, 10] have also or as
Viewpoint WHO, the Global Fund, and medical malpractice in malaria Amir Attaran, Karen I Barnes, Christopher Curtis, Umberto d’Alessandro, Caterina I Fanello, Mary R Galinski, Gilbert Kokwaro, Sornchai Looareesuwan, Michael Makanga, Theonest K Mutabingwa, Ambrose Talisuna, Jean François Trape, William M Watkins In 1998, WHO launched a new, high profile campaign todoubled childhood ma